Pfizer Presents Results from Two Phase 3 TRUMENBA Studies at the European Society for Paediatric Infectious Diseases Meeting

By: via Benzinga
Pfizer Inc. (NYSE: PFE) today announced results of two Phase 3 studies demonstrating the immunogenicity of TRUMENBA® (Meningococcal ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.